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The Jefferson Center For Diabetic
Kidney Disease
End-stage renal disease from diabetes carries with it a risk of death that few people
appreciate. Patients with this disease carry greater risk of death within five years
than patients with newly diagnosed HIV or newly diagnosed breast cancer. Diabetic
nephropathy has increased enormously and now accounts for over 40% of all new
cases of endstage renal failure in the United States.1 Over the past 20 years,
diabetic nephropathy has increased over ten-fold in incidence in the state of
Pennsylvania.1
What are the factors underlying this alarming trend? With the knowledge gained
from studies showing the benefits of ACE inhibitors in reducing proteinuria and
retarding progressive renal disease2, it was assumed that diabetic nephropathy
would soon be another victim of medical success. This has not proved to be the case
for several reasons: 1) the pool of patients with the potential to develop nephropathy
has increased due to both better medical care and to the increasing number of obese
adult-onset diabetic patients, and 2) ACE inhibitors can decrease the rate of
progression, but only if the patients attain optimal blood pressure control.
Based on two large clinical trials, the target blood pressure for the diabetic patient
with proteinuria should be less than 150/85 mm Hg and ideally at 125/75 mm Hg 3,4.
The challenge of caring for the diabetic patient with evidence of kidney disease is to
protect those remaining delicate nephrons from being exposed to ongoing high blood
pressures and elevated blood sugars. Careful attention to these basic issues can
mean the difference between prolonged preservation of adequate renal function and
the need for renal replacement therapy. Delivering optimal care to these patients
remains an ongoing challenge to the physician. At Jefferson, we have formed a
Center for Diabetic Kidney Disease (CDKD) to increase both public awareness of
diabetic nephropathy and to educate physicians about the importance of aggressive
intervention. The CDKD at Jefferson integrates the resources of clinicians and
researchers from the divisions of Nephrology and Endocrinology to provide intensive
management of the patient with established diabetic nephropathy. Patients benefit
from receiving care in one team-oriented setting with nephrologists,
endocrinologists, and dieticians working closely together and in coordination with the
primary care physician. The CDKD has evaluated and managed more than 300
patients since its inauguration in 1996.
Current clinical research studies at the CDKD are focused on determining optimal
blood pressure lowering agents, evaluating new anti-fibrotic agents that may prevent
progression of nephropathy, and identifying DNA polymorphisms and other markers
that may predict the incidence and progression of nephropathy. To schedule an
appointment or for more information about the Jefferson Center for Diabetic Kidney
Disease, please call 215-503-6950.
(Members of the Center for Diabetic Kidney Disease include Serge Jabor,
endocrinologist; Tracy McGowan, nephrologist and clinical research investigator;
Barbara Whedon, nutritionist; Barbara Francos, clinical research coordinator; and
Dana Wames, administrator.)
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